Thymidine Kinase 2 Deficiency (TK2D) is a severe mitochondrial disorder characterized by progressive neuromuscular degeneration and respiratory failure. The treatment landscape is expanding through cutting-edge research in gene therapy and nucleotide supplementation. Pharmaceutical innovators like Modis Therapeutics (acquired by Zogenix), Ultragenyx, and ReGenX Biosciences are advancing promising clinical-stage therapies to address this devastating condition with high unmet medical need.
Download the Complete TK2D Market Report:
https://www.delveinsight.com/i....nfographics/thymidin
כמו
תגובה
לַחֲלוֹק
